Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 1,644,862Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels
In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)       Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted  AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.  

Impressions: 2897

https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels

#PharmaFlow by PHARMACOMPASS
24 Apr 2025

STOCK RECAP #PipelineProspector

read-more
read-more
Pipeline Prospector 2023 highlights: Obesity drugs perk up Lilly, Novo sales; ADCs spur dealmaking
The year 2023 was marked by volatility. The good news is that despite factors like inflation, interest rate hikes and the two ongoing wars, pharma indices ended the year in the green. Though growth was nowhere close to S&P 500’s remarkable 24 percent rise, the Nasdaq Biotechnology Index (NBI) gained a modest 3 percent and rose to 4,370.58, while the SPDR S&P Biotech ETF (XBI) grew 6 percent to 89.29 in 2023. And the S&P Biotechnology Select Industry Index (SPSIBI) ended the year higher by 8 percent, at 6,954.64. Many saw 2023 as the first year post the pandemic. Clearly, attention turned away from Covid-19 to handling one of the world’s biggest epidemics – obesity. Novo Nordisk and Eli Lilly outshone other drugmakers in 2023, as their newly launched weight management drugs became immensely popular. Falling under the class of drugs known as glucagon-like peptide 1 (GLP-1) agonists, these drugs were originally launched to improve blood sugar control in those with type 2 diabetes. The year also saw respiratory syncytial virus (RSV) vaccines hitting the markets. Another noteworthy debut was Casgevy, a therapy based on Nobel Prize-winning CRISPR technology that uses molecular “scissors” to trim faulty parts of “sickle” shaped cells that cause the highly debilitating sickle cell disease. The year’s biggest M&A deal was Pfizer’s acquisition of Seagen for US$ 43 billion. As the year drew to a close, we saw significant M&A activity, with Bristol Myers Squibb acquiring Karuna Therapeutics for US$ 14 billion and RayzeBio for US$ 4.1 billion.Access the Pipeline Prospector Dashboard for December 2023 Newsmakers (Free Excel)  Lilly, Novo Nordisk leap ahead with anti-obesity drugs; Roche, Astra join GLP-1 race Eli Lilly saw its sales rise by 17 percent in the first nine months of 2023, at US$ 24.77 billion, on the back of rising sales for Mounjaro (tirzepatide) of US$ 2.96 billion along with other diabetes and weight management drugs during the period. Novo’s sales rose 33 percent in the same period to DKK 166.4 billion (US$ 24.4 billion) from DKK 128.87 billion (US$ 18.9 billion) in the corresponding period of 2022. Wegovy (semaglutide) accounted for sales of DKK 21.73 billion (US$ 3.19 billion) compared to sales of just DKK 3.74 billion (US$ 0.55 billion) in 2022, a rise of 492 percent. Ozempic’s (semaglutide) sales rose to DKK 65.65 billion (US$ 9.63 billion) in the first nine months of 2023, compared to DKK 42.77 billion (US$ 6.03 billion) in 2022, a rise of 58 percent.  The anti-obesity market is projected to increase to US$ 100 billion by 2030. While existing players are busy expanding capacities for their GLP-1 drugs, more players are eager to enter this market to cash in on the opportunity. In December, Roche bought Carmot Therapeutics for US$ 2.7 billion, thereby getting its hand on CT-388, a promising once-a-week injection currently in mid-stage trials. Similarly, AstraZeneca entered into a potential US$ 2 billion deal with Eccogene for the experimental oral drug ECC5004 for obesity, type-2 diabetes, and other cardio-metabolic conditions. Merck’s GLP-1 strategy is to come up with treatments whose benefits go beyond weight loss. Its investigational GLP-1 drug efinopegdutide for non-alcoholic steatohepatitis (NASH) demonstrated compelling weight-loss benefits. This experimental drug has won the FDA’s Fast Track designation for treating NASH. Access the Pipeline Prospector Dashboard for December 2023 Newsmakers (Free Excel) Pfizer enters ADC space with US$ 43 bn Seagen buy; BMS buys Karuna for US$ 14 bn After GLP-1 drugs, antibody-drug conjugates (ADCs) have emerged as another big growth area. ADCs are designed as a targeted therapy for treating disease, and are being widely used for the management or treatment of cancer. Pfizer invested some of the cash it accumulated from its Covid sales to buy out Seagen for US$ 43 billion. The ADC space also saw AbbVie pick up ImmunoGen for US$ 10.1 billion and Merck sign a potential US$ 22 billion deal with Daiichi Sankyo. The other big deals of 2023 include BMS’ acquisition of Karuna Therapeutics for US$ 14 billion and Merck’s buyout of Prometheus and its potential best-in-class candidate to treat ulcerative colitis and Crohn’s disease for US$ 10.8 billion. Similarly, AbbVie acquired neuroscience drugmaker Cerevel Therapeutics for about US$ 8.7 billion in the hope of shoring up its revenues that have been hit by generic competition to its blockbuster Humira (adalimumab). Access the Pipeline Prospector Dashboard for December 2023 Newsmakers (Free Excel)  Pfizer, BioNTech, Moderna post lower revenues due to plummeting Covid-19 sales Pfizer reported a 42 percent drop in revenues in the first nine months of 2023 — at US$ 44.25 billion down from US$ 76.04 billion in the same period of 2022 — owing to disappointing sales of its Covid products. Comirnaty sales dropped 77 percent from US$ 26.48 billion to US$ 5.86 billion, and revenue from Paxlovid was down 73 percent at US$ 4.41 billion, from US$ 17.1 billion in 2022. Pfizer’s Comirnaty partner BioNTech was worse hit, and saw an 82 percent decline in total sales at € 2.34 billion (US$ 2.56 billion) compared to € 13.03 billion (US$ 14.25 billion) in the first three quarters of 2022. Meanwhile, Moderna’s sales plunged 71 percent in the same period to US$ 4.04 billion, compared to US$ 14.18 billion in 2022. Access the Pipeline Prospector Dashboard for December 2023 Newsmakers (Free Excel)  FDA okays gene therapies for sickle cell disease, RSV vaccines from GSK, Pfizer  The year saw the United Kingdom and the US approve the world’s first human gene therapy for sickle-cell disease (SCD). The US Food and Drug Administration (FDA) not only approved CRISPR Therapeutics and Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) for SCD, it also approved bluebird bio’s Lyfgenia (lovotibeglogene autotemcel) for the treatment of SCD in patients aged 12 and older who have a history of vaso-occlusive events (when sickled red blood cells block blood flow to the point that tissues become deprived of oxygen). In May, FDA approved GSK’s RSV vaccine Arexvy for people aged 60 and older. Arexvy is the first RSV vaccine to be approved in the US for the common condition that can be fatal for the elderly. Less than a month later, Pfizer’s RSV vaccine Abrysvo also got approved. In July, FDA approved Sanofi and AstraZeneca’s preventive RSV antibody therapy Beyfortus (nirsevimab-alip) for newborns and infants. RSV is the number one cause of infant hospitalization in the US. Access the Pipeline Prospector Dashboard for December 2023 Newsmakers (Free Excel)  Our view A strong portfolio and drug pipeline can help drugmakers sail through the toughest economic and regulatory environment. While it’s difficult to say how things will pan out in 2024, we do know that several pathbreaking drugs are coming up for approval by the FDA early this year, including Madrigal Pharmaceuticals’ resmetirom (the first treatment for NASH with liver fibrosis), Merck’s sotatercept (a treatment for pulmonary arterial hypertension) and, later, in September, Karuna Therapeutics’ drug to treat schizophrenia. In short, there is much to look forward to in 2024.Access the Pipeline Prospector Dashboard for December 2023 Newsmakers (Free Excel) 

Impressions: 3067

https://www.pharmacompass.com/pipeline-prospector-blog/pipeline-prospector-2023-highlights-obesity-drugs-perk-up-lilly-novo-sales-adcs-spur-dealmaking

#PharmaFlow by PHARMACOMPASS
11 Jan 2024

NEWS #PharmaBuzz

read-more
read-more

https://www.contractpharma.com/breaking-news/celltrions-yuflyma-approved-as-interchangeable-biosimilar-to-humira/

CONTRACTPHARMA
15 Apr 2025

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761299

FDA
14 Feb 2025

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761154

FDA
05 Feb 2025
Will Epygen’s biosimilars bets pay off?
Will Epygen’s biosimilars bets pay off?

04 Jan 2025

// EXPRESSPHARMA

https://www.expresspharma.in/will-epygens-biosimilars-bets-pay-off/

EXPRESSPHARMA
04 Jan 2025

https://www.fiercepharma.com/marketing/humira-cosentyx-gaining-favor-treatments-hidradenitis-suppurativa-more-support-biologics

FIERCE PHARMA
11 Nov 2024

https://www.fiercepharma.com/pharma/abbvies-skyrizi-snatches-immunology-crown-falling-humira-becoming-top-sales-driver-company

FIERCE PHARMA
31 Oct 2024